| Prev Close | 18.60 |
| Day Low/High | 18.29 / 18.87 |
| 52 Wk Low/High | 15.68 / 31.81 |
| Avg Volume | 990.10K |
Heron Therapeutics Inc. (HRTX)
18.45
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 88.39M |
| Market Cap | 1.64B |
| EPS | -2.40 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Dealing With Biotech Stocks That Face Setbacks
Knowing when to continue to fish or cut bait is something that develops over time in this space.
These 3 Biotech Stocks Are Moving Closer to Profitability
Here are updates on small biotech/biopharma names I have profiled before.
3 Promising Small Biotech Stocks to Watch
I think there is still upside left in a variety of smaller names especially if M&A activity picks up across the industry.
Markets Struggle to Find Direction
Markets continue to meander between being slightly up or slightly down as equities struggle for a direction after yesterday's big slide. New homes sales for the month of February were above expectations with the average selling price 10% above the s...
Consider These Tier 3 Biotechs
I hope we get a decent size market decline so I can add to some stakes in what I think are already undervalued biotech holdings.
Biotech Shows Strength
The major indices have improved a tad since our last update. Biotech has shown some strength over the past two hours or so. There are two names to keep an eye on: T2 Biosystems has been strong so far in 2018, moving from around $4 to over $5 a shar...
5 Small Biotechs Receive Shots in the Arm
Favorable quarterly results and FDA drug approvals should help lift these five names.
5 Small Biotechs Receive Shots in the Arm
Favorable quarterly results and FDA drug approvals should help lift these five names.
Market Wrap: Stocks Sink Across the Board
Materials and technology names led the way down on the session.
Bearish Charts of the Week: SPY, IWM
The markets have given us lots to think about here.
More Morning Musings
It appears based on the futures that the market's rally will continue today, at least at the open. Personally, I think investors are becoming complacent given what could unfold in Greece over the next week. Everyone seems to be betting that Europe w...
Where the Money Was Made the Last 5 Years
Only one fund category (of 20) has beaten the S&P 500 over half a decade.